Origin Biosciences, Inc.

ACTIVE

1800 Owens St Ste C1200, 加利福尼亚州圣克拉拉县, California, United Stateswww.origintx.comSubsidiary11–50 employeesEstablished: 2018-01-01

Part of BRIDGEBIO PHARMA LLC

Clinical Trials

5 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2018

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

83.3%

Phase 2

16.7%

Trial Status Distribution

Active, not recruiting

83.3%

Recruiting

16.7%

Clinical Trials

Trials sponsored by this organization (6)

STUDY OF ORGN001 IN NEWBORNS, INFANTS, CHILDREN AND ADOLESCENTS WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A

Phase 1

Active, not recruiting

Nov 20208 participants

STUDY OF ORGN001 IN NEWBORNS, INFANTS AND CHILDREN WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A

Phase 1

Active, not recruiting

Nov 201510 participants

STUDY OF ALXN1101 IN NEWBORNS WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A

Phase 1

Active, not recruiting

Nov 201510 participants

Safety and efficacy of ORGN001 in pediatric patients with Molybdenum Cofactor Deficiency Type A

Phase 1

Active, not recruiting

Jan 20148 participants

Safety and efficacy of ORGN001 in pediatric patients with Molybdenum Cofactor Deficiency Type A

Phase 1

Active, not recruiting

Dec 20138 participants

A Phase 2, Multicenter, Multinational, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of ORGN001 (formerly ALXN1101) in Pediatric Patients with Molybdenum Cofactor Deficiency (MoCD) Type A Currently Treated with Recombinant Escherichia coli-derived Cyclic Pyranopterin Monophosphate (rcPMP)

Approvals

No approval data available

News

No news articles found

Back to Organizations